RYTM · Rhythm Pharmaceuticals, Inc.

Track RYTM — free

$92.83 -0.58 (-0.62%)

Russell 2000 member Rebalance outlook locked

Market Cap

$6.79B

68.85M

Volume · Oct 2 502.1K Avg daily vol (3M) 647.97K

Up next

Next earnings call

Oct 14, 2026 Est · unconfirmed · in 2 wks

Latest filing: 10-Q

filed Aug 4, 2026

Q2 2026 earnings call transcript

call held Aug 4, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

View all 115 metrics

Revenue (TTM)

$239.92M

Trailing 12 months

Net income (TTM)

−$205.35M

Trailing 12 months

Revenue growth YoY

+46.9%

Year over year

Operating margin

-83.6%

Trailing 12 months

P / E (TTM)

—

Trailing earnings

FCF yield

—

TTM · current market cap

Return on invested capital

—

Trailing 12 months

Net cash

$224.79M

Latest balance sheet

Dividend yield

—

Trailing 12 months

Shares change YoY

+7.7%

Year over year · more shares

Price change (1Y)

-6.6%

Trailing year

Short interest

14.9%

Latest settlement · 20.1 days to cover

View all 115 metrics

Equibles Rating

blended score · not investment advice

Overall

Sell

SellHoldBuy

Technical Sell Momentum Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 16.4 · calm Equity put/call 0.57

Technical

price trend

Sell

50 / 200-day cross No cross

Price vs 200-day avg −6%

below

Price vs 50-day avg −12%

below

RSI (14) 30

neutral

MACD trend Negative

52-week position 42%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Weak

1-month return −11%

trailing

6-month return +11%

trailing

YTD return −13%

this year

Relative strength −2%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) No cross

50d $106 › 200d $99 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +64 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

14.94% of float · ▼ -0.1% MoM · 20.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

307 holders — near 3-yr high, broad support

Squeeze score 63

elevated · 0–100

Fundamentals

Fair

EPS growth +28%

Y/Y

Free cash flow $-116.6M

Balance sheet $53.9M

net debt

Quant / Vol

risk profile

Very High

Volatility 47%

annualized · 1-yr

Max drawdown −36%

past year

ATR 4.1%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Latest guidance · from the 8-K filed Aug 4, 2026

year ending December 31, 2026

Non-GAAP Operating Expenses Non-GAAP Initiated $363M – $397M

2026

Anticipated non-GAAP Operating Expenses Non-GAAP $363M – $397M

SG&A (non-GAAP Operating Expenses) Non-GAAP $188M – $202M

R&D (non-GAAP Operating Expenses) Non-GAAP $175M – $195M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell

3 · 4 · 0

50 / 200-day cross

No cross Neutral

Price vs 200-day avg

−6% Bearish

Price vs 50-day avg

−12% Bearish

RSI (14)

30 Neutral

MACD trend

Negative Bearish

52-week position

42% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 3 of 6

Trend (MA cross) No cross

50d $106 › 200d $99 — 50d above 200d

Institutional flow Accumulating

+7% holders QoQ · +64 funds added

Insider flow Flat

No net insider activity over 90 days

Short interest Falling

14.94% of float · ▼ -0.1% MoM · 20.1 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

307 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $76 Now $93 · 42% Range high $118

vs 200-day avg -6% vs 50-day avg -12%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
RYTM Rhythm Pharmaceuticals, Inc. this stock	$6.79B	-12.7%	+45.8%	—	14.9%
VRTX Vertex Pharmaceuticals Inc / Ma	$133.37B	+11.8%	+46.2%	30.7	1.9%
REGN Regeneron Pharmaceuticals, Inc.	$81.13B	-4.8%	+20.8%	19.5	2.5%
MRNA Moderna, Inc.	$79.40B	+540.7%	+4.3%	—	8.2%
CSLLY Csl Ltd	$61.25B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Accumulating

Holders

307

% held: 112.5%
Net QoQ: +3.7M sh
Top holder: RA CAPITAL MANAGEMENT, L.…

Held Float

View

Held by Funds

Fund positions

342

View

Short & Settlement

Short Interest Falling

Shares short

10.3M

Days to cover: 20.1d
Change: -15.2K sh

View

Short Volume

Short vol %

46%

As of: Oct 1, 2026

Short Total

View

Fails to Deliver

FTD shares

4.0K

Value: $453.1K
As of: Aug 26, 2026

View

Off-Exchange

Off-exchange %

44.3%

Week of: Aug 24, 2026

Off-exch Lit

View

Financials

Revenue (FY)

$189.8M

Net income (FY): $-196.5M
EPS diluted: $-3.11

View

Filings

SEC Filings

Latest

Investor Event Transcript

Filed: Sep 15, 2026
This year: 18

View

Proposed Sales

Value

$5.2M

Shares: 50.0K
Filed: Sep 14, 2026

View

Earnings & Events

Webcasts

Last webcast

Sep 15, 2026

View

Performance

	5D	20D	120D	MTD	YTD
RYTM	-5.0%	-11.4%	+10.7%	-1.9%	-12.7%
SPY	-0.4%	-0.2%	+12.4%	+0.2%	+12.0%
vs SPY	-4.6%	-11.2%	-1.8%	-2.1%	-24.8%

Key facts CIK 1649904 CUSIP 76243J105 13F (30d) 9 filings 9 filers Visit website Investor relations

RYTM · Rhythm Pharmaceuticals, Inc.

Price & Indicators

Up next

Metrics snapshot

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance